We released our Second Quarter 2025 financial results and corporate update today. To read the full earnings press release, click here: bit.ly/4mwLqh0
$ATYR
Today we announced that the last patient has completed their last visit in our Phase 3 EFZO-FIT™ study of efzofitimod in patients with #pulmonarysarcoidosis. We look forward to sharing topline results later this quarter. Read more: bit.ly/4f5DnW4
i'm short $ATYR and predict the stock will drop 80% in the next 4 to 6 weeks. some of the worst data i've ever seen. really bad drug, really tough disease. as confident as $SAVA $INMB $GALT etc